Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,650.79
(
0.23%
)
News Focus
News Focus
Post# of 470
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Stumblebum

Send PM Follow Ignore
Followers 11
Posts 1643
Boards Moderated 3
Alias Born 05/02/2019

Stumblebum

Re: rosemountbomber post# 449

Monday, 02/16/2026 3:56:16 PM

Monday, February 16, 2026 3:56:16 PM

Post# of 470
As of February 16, 2026, Sanofi is actively pursuing an acquisition of Ocular Therapeutix (NASDAQ: OCUL) and is preparing a "sweetened," higher bid after a previous offer was rejected, reported by MarketMinute. The potential deal is centered on Ocular's lead drug candidate for wet AMD, Axpaxli, with pivotal Phase 3 results expected on February 17, 2026, according to FinancialContent.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent OCUL News
More OCUL News